1. RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis
- Author
-
Daniela Pankova, Eduard Willms, David Cano-Rodriguez, Eric O'Neill, Anna M. Grawenda, Alex von Kriegsheim, Sander C. Steenbeek, Matthew J.A. Wood, Christiana Kartsonaki, Nikola Vlahov, Maria Laura Tognoli, Jacco van Rheenen, Michael Eyres, Simon Scrace, Marianne G. Rots, Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Subjects
Mice, SCID ,Metastasis ,PATHWAY ,Mice ,Cell Movement ,BINDING ,AC133 Antigen ,Cancer ,General Neuroscience ,Extracellular vesicle ,Nanog Homeobox Protein ,Articles ,Cell biology ,Gene Expression Regulation, Neoplastic ,src-Family Kinases ,DNA methylation ,MCF-7 Cells ,Neoplastic Stem Cells ,Female ,Stem cell ,extracellular vesicles ,Signal Transduction ,gene methylation ,SRC ,Homeobox protein NANOG ,amoeboid motility ,TUMOR-CELL INVASION ,BIOLOGY ,Breast Neoplasms ,Biology ,Rho/ROCK pathway ,General Biochemistry, Genetics and Molecular Biology ,Aldehyde Dehydrogenase 1 Family ,Article ,Cancer stem cell ,RHO ,Cell Line, Tumor ,Spheroids, Cellular ,REVEALS ,medicine ,Animals ,Humans ,Molecular Biology ,Cell Proliferation ,General Immunology and Microbiology ,Oncogene ,Tumor Suppressor Proteins ,DNA Methylation ,medicine.disease ,Survival Analysis ,Xenograft Model Antitumor Assays ,ROCK pathway ,RASSF1C oncogene ,MODES ,CpG Islands ,Cell Adhesion, Polarity & Cytoskeleton ,rhoA GTP-Binding Protein ,MATRIX - Abstract
Cell plasticity is a crucial hallmark leading to cancer metastasis. Upregulation of Rho/ROCK pathway drives actomyosin contractility, protrusive forces, and contributes to the occurrence of highly invasive amoeboid cells in tumors. Cancer stem cells are similarly associated with metastasis, but how these populations arise in tumors is not fully understood. Here, we show that the novel oncogene RASSF1C drives mesenchymal‐to‐amoeboid transition and stem cell attributes in breast cancer cells. Mechanistically, RASSF1C activates Rho/ROCK via SRC‐mediated RhoGDI inhibition, resulting in generation of actomyosin contractility. Moreover, we demonstrate that RASSF1C‐induced amoeboid cells display increased expression of cancer stem‐like markers such as CD133, ALDH1, and Nanog, and are accompanied by higher invasive potential in vitro and in vivo. Further, RASSF1C‐induced amoeboid cells employ extracellular vesicles to transfer the invasive phenotype to target cells and tissue. Importantly, the underlying RASSF1C‐driven biological processes concur to explain clinical data: namely, methylation of the RASSF1C promoter correlates with better survival in early‐stage breast cancer patients. Therefore, we propose the use of RASSF1 gene promoter methylation status as a biomarker for patient stratification., Tumour‐suppressor RASSF1A encodes an alternative transcript, RASSF1C, that acts as oncogene in human breast cancer, triggering pro‐invasive cellular features and aggressiveness.
- Published
- 2021